EN DE
Watch CHA Vaccine Institute Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CHA Vaccine Institute Co. Ltd. (261780) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CHA Vaccine Institute Co. Ltd. stock KRW 1,966, price KRW 4,125, that is 52.4% below the price, quality 31 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

CV CHA Vaccine Institute Co. Ltd. logo Thin data Nov 10, 2026

CHA Vaccine Institute Co. Ltd.

261780 · KQ
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Low debt
Fair value 1,966 KRW · Strongly overvalued
Quality 31/100
Weak Growth (revenue 3y −4.0 %/yr in KRW)
Negative free cash flow
Trails peers (1/7)
Narrow moat 6/100
Thin data
Estimate
Watch CHA Vaccine Institute Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

13,000 KRW 1,857 KRW Fair Value 1,966 KRW Oct 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 1,857 KRW – 13,000 KRW · fair‑value band 1,474 KRW – 2,457 KRW · the 4,125 KRW price screens above the 1,966 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CHA Vaccine Institute Co. in your weekly email

Every Wednesday you see whether CHA Vaccine Institute Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases.

Show moreShow less

Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment.

It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious disease suppression, and a TB booster vaccine.

The company also develops 3rd-generation Hepatitis B vaccine (CVI HBV 001), a preventive vaccine using 3rd generation recombinant antigens; Hepatitis B therapeutic vaccine (CVI HBV 002), a therapeutic vaccine for treatment of patients and carriers of chronic hepatitis B; Shingles vaccine (CVI VZV 001), for prevention of shingles and postherpetic neuralgia; Next generation flu vaccine, quadrivalent influenza vaccine; Immunostimulant, TLR ligand based immunoreactive substances for immune response to vaccines; Recombinant MBL, immunotherapeutic substances infections by viruses and bacteria.

The company was formerly known as CHA Vaccine Research Institute and changed its name to AriBioLab Co.,Ltd. in May 2026. AriBioLab Co.,Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.

Stock analysis

CHA Vaccine Institute Co. Ltd. (261780) currently trades at 4,125 KRW, while our estimate is 1,966 KRW, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,474 KRW (bear) to 2,457 KRW (bull), the price of 4,125 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CHA Vaccine Institute Co. Ltd. reported revenue of 159M KRW in FY2025 versus 500M KRW in FY2021, a compound −25.0%/yr. Reported net income was −16.0B KRW in FY2025.

Key figures

Market cap 111B KRW (≈ $83.1M) Micro · EPS (TTM) −535.78 KRW · Return on equity −92.3% · Return on assets (EBIT) −19.7% (5-year average) · Operating margin −7,492% · Revenue (TTM) 173M KRW · Revenue growth (YoY) +204% · Free cash flow −11.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 122% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −52%, 261780 screens richer than that median.

Fair Value

Bear 1,474 KRW Fair Value 1,966 KRW Bull 2,457 KRW
Price 4,125 KRW · Downside -52.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 77
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−57.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,442.9% (2020) → −8,997.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

261780 screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CHA Vaccine Institute Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −52.4% · Bottom 25%
Profitability
Return on assets −53.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 204.1% · Top 25%
Balance sheet
Debt / equity 0.39× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 9.34× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)81 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 261780
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 261780
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 261780
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 261780
argenx SE ARGX $971.55 $908.40 −7% vs 261780
CSL Limited CSL A$201.68 A$181.40 −10% vs 261780
Moderna, Inc MRNA $250.83 $158.70 −37% vs 261780
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 261780
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 261780
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 261780

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CHA Vaccine Institute Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CHA Vaccine Institute Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/261780

Frequently asked questions

Is CHA Vaccine Institute Co. Ltd. (261780) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,966 KRW versus a price of 4,125 KRW, about 52% lower (overvalued).
What is the fair value of 261780?
Our estimate for CHA Vaccine Institute Co. Ltd. is 1,966 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 4,125 KRW.
What is the quality score of 261780?
CHA Vaccine Institute Co. Ltd. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHA Vaccine Institute Co. Ltd. (261780)?
Our calculated price target is the estimate of 1,966 KRW (as of Nov 10, 2026). Cautious scenario 1,474 KRW, optimistic scenario 2,457 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CHA Vaccine Institute Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 1,966 KRW, about 52% lower versus a price of 4,125 KRW (overvalued). Cautious scenario 1,474 KRW, optimistic scenario 2,457 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CHA Vaccine Institute Co. Ltd. (261780)?
CHA Vaccine Institute Co. Ltd. reported trailing-twelve-month revenue of about 173M KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CHA Vaccine Institute Co. Ltd. (261780)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHA Vaccine Institute Co. Ltd. it is 1,966 KRW per share (as of Nov 10, 2026), against a price of 4,125 KRW.
Is CHA Vaccine Institute Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 261780 trades above its calculated fair value: price 4,125 KRW, fair value 1,966 KRW, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 261780?
No. The price is what the market pays today (4,125 KRW); the fair value is what the company's own numbers justify (1,966 KRW). For CHA Vaccine Institute Co. Ltd. the two are 2,159 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CHA Vaccine Institute Co. Ltd. worth?
The market values CHA Vaccine Institute Co. Ltd. at about 111B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 4,125 KRW; our models calculate a fair value of 1,966 KRW per share.
What do the bullish and bearish scenarios say about 261780?
Our models span a range for CHA Vaccine Institute Co. Ltd.: cautious scenario 1,474 KRW, base 1,966 KRW, optimistic 2,457 KRW per share (as of Nov 10, 2026, price 4,125 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CHA Vaccine Institute Co. Ltd. (261780)?
Balance-sheet figures for CHA Vaccine Institute Co. Ltd. (as of Nov 10, 2026): return on equity −92.3%, debt of 0.39 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 261780 from its 52-week high?
CHA Vaccine Institute Co. Ltd. trades at 4,125 KRW, about 28% below its 52-week high of 5,700 KRW and 122% above the low of 1,857 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,966 KRW is for.
Which stocks are comparable to CHA Vaccine Institute Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHA Vaccine Institute Co. Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 4,125 KRW, calculated fair value 1,966 KRW (−52%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CHA Vaccine Institute Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHA Vaccine Institute Co. Ltd. (261780)?
The closing price on Nov 10, 2026 was 4,125 KRW. Our estimate is 1,966 KRW, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHA Vaccine Institute Co. Ltd. right now?
The price sits above even our optimistic bull case (2,457 KRW). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CHA Vaccine Institute Co. Ltd.

How large is the market capitalisation of CHA Vaccine Institute Co. Ltd. (261780)?
The market capitalisation of CHA Vaccine Institute Co. Ltd. is 111B KRW (≈ $83.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CHA Vaccine Institute Co. Ltd. (261780)?
Earnings per share at CHA Vaccine Institute Co. Ltd. are −535.78 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CHA Vaccine Institute Co. Ltd. (261780)?
The return on equity (ROE) of CHA Vaccine Institute Co. Ltd. is −92.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHA Vaccine Institute Co. Ltd. (261780)?
On an EBIT basis the return on assets of CHA Vaccine Institute Co. Ltd. is −19.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHA Vaccine Institute Co. Ltd. (261780)?
The operating margin of CHA Vaccine Institute Co. Ltd. is −7,492% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CHA Vaccine Institute Co. Ltd. (261780)?
Revenue at CHA Vaccine Institute Co. Ltd. is growing +204% versus a year earlier (3y avg −4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CHA Vaccine Institute Co. Ltd. (261780) generate?
The free cash flow of CHA Vaccine Institute Co. Ltd. is −11.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CHA Vaccine Institute Co. Ltd. (261780) carry?
The net debt of CHA Vaccine Institute Co. Ltd. is 20.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CHA Vaccine Institute Co. Ltd. in the live analysis

One click puts CHA Vaccine Institute Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.